Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy Lymphatic-delivery-composition

 Quercetin derivatives and their medical usages
The invention claimed is: 1. A purified compound of formula I ##STR00002## wherein R.sub.1, R.sub.2,...


 Islet cells from human embryonic stem cells
This invention solves the problem of generating large populations of human islet cells by showing ...


 Neural thread protein gene expression and detection of alzheimer's disease
A need exists for a definitive diagnostic test which can be performed on individuals suspected of ...


 Method of detecting neurological disease or dysfunction
What is claimed is: 1. A method for detecting the presence of nPTP in a human subject, said method ...


 Metabolic pathway assay
This invention relates to an in vitro screening assay which identifies enzyme inhibitors. This ...


 MurC
What is claimed is: 1. An isolated polynucleotide segment comprising a first polynucleotide ...


 Murf gene and enzyme of Pseudomonas aeruginosa
Polynucleotides and polypeptides of Pseudomonas aeruginosa MurF, an enzyme involved in bacterial ...


 Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold
It is an object of the invention to provide a method of affecting nociception. It is an object of ...


 Liposomal transfection method
The object of the present invention is thus a method for transfecting a cell with a nucleic acid ...


 Antihelminthic anthraquinones and method of use thereof
OF THE INVENTION All patents, patent applications, government publications, government regulations,...


 Lymphatic delivery composition

Details
Inventors: Davis, Stanley S.; Illum, Lisbeth; Christy, Nicola; Moghimi, Moein;
Assignee: Danbiosyst UK Limited (Nottingham, GB)
Primary Examiner: Clardy; S. Mark
Assistant Examiner: Harrison; Robert H.
Attorney, Agent or Firm: Arnall, Golden & Gregory, LLP

A composition for delivering an active agent to the lymphatic system comprises a plurality of colloidal particles and an active agent associated with each particle, wherein the surface of each particle has a hydrophobicity ratio of less than 10 as defined by hydrophobic interaction chromatography.

DETAILED DESCRIPTION We claim: 1.
A composition capable of delivering an active agent to the lymphatic system comprising a plurality of colloidal particles having an active agent associated with each particle, wherein the particles consist essentially of particles having a size in the rage of between one and 250 nm and the surface of each particle has a hydrophobicity ratio determined by hydrophobic interaction chromatography of less than or equal to about 10.
2.
The composition of claim 1 wherein the hydrophobicity ratio is less than 5.
3.
A composition capable of delivering an active agent to the lymphatic system comprising a plurality of colloidal particles and an active agent associated with each particle, wherein a modifying agent is adsorbed onto or attached to the surface of each particle, such that the modifying agent gives and advancing contact angle of less than about 60.
degree.
.
4.
A composition capable of delivering an active agent to the lymphatic system comprising a plurality of colloidal particles and an active agent associated with each particle wherein a modifying agent is adsorbed onto or attached to the surface of each particle such that the thickness of the layer of modifying agent is about 0.
8 to 4.
0 nm.
5.
A composition capable of delivering an active agent to the lymphatic system comprising a plurality of colloidal particles and an active agent associated with each particle wherein a modifying agent is adsorbed onto or attached to the surface of each particle such that the albumin uptake ratio (AUR) of the surface is between about 0.
2 and 0.
5.
6.
A composition capable of delivering an active agent to the lymphatic system comprising a plurality of colloidal particles and an active agent associated with each particle wherein a modifying agent is adsorbed onto or attached to the surface of each particle such that the thickness of the layer of modifying agent is less than about 10 nm and the surface of each particle has a hydrophobicity ratio of less than 5.
7.
The composition of claim 3 wherein the modifying agent is adsorbed onto or attached to the surface of each particle such that the thickness of the layer of modifying agent is less than about 10 nm



Related patents
  Biocompatible microcapsules
This invention for the first time demonstrates the use of water soluble non-ionic polymers such as PEO to create resistance to cell adhesion on the surface of ...
  Composotions and methods for radiographic imaging
The present invention is a micellar iodine-containing block copolymer (MICBC) useful as a radiographic imaging agent. These micelle-forming block copolymers include a ...
  Biocompatible microcapsules
This invention for the first time demonstrates the use of water soluble non-ionic polymers such as PEO to create resistance to cell adhesion on the surface of ...
  Adeno-associated viral vector-based methods and compositions for introducing an expression cassette into a cell
What is claimed is: 1. A method for introducing a functional expression cassette into a cell, said method comprising: (a) providing a population of first and second ...
  Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
What is claimed is: 1. A process for producing a phospholipid- or lipid-linked glycosaminoglycan represented by the following formula (VI), ##STR122## or a salt thereof, ...
  Inhibition of excessive phospholipase A.sub.2 activity and/or production by non-antimicrobial tetracyclines
The present invention provides a method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production which ...
  Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
OF THE INVENTION The invention describes methods and compositions for the treatment of rheumatoid arthritis and osteoarthritis and other conditions that manifest ...
  A3AR agonists for the treatment of inflammatory arthritis
The invention is described in the following SUMMARY with reference to a therapeutic method for the treatment of inflammatory arthritis. It should be noted that in ...
  Nucleic acids encoding high molecular weight major outer membrane protein of moraxella
The present invention is directed towards the provision of purified and isolated major outer membrane protein of Moraxella catarrhalis and other Moraxella strains, ...
  Saponin adjuvant compositions
What is claimed is: 1. A Quillaja saponaria saponin composition for eliciting an immune response in an organism, comprising a combination of a substantially pure QS-7 ...

0.034

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved